Staphylococcus aureus vaccine for orthopedic patients: An economic model and analysis

Bruce Y. Lee; Ann E. Wiringa; Rachel R. Bailey; G. Jonathan Lewis; Jared Feura; Robert R. Muder

doi:10.1016/j.vaccine.2009.12.075

Staphylococcus aureus vaccine for orthopedic patients: An economic model and analysis

Bruce Y. Lee, Ann E. Wiringa, Rachel R. Bailey, G. Jonathan Lewis, Jared Feura, Robert R. Muder

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

To evaluate the potential economic value of a Staphylococcus aureus vaccine for pre-operative orthopedic surgery patients, we developed an economic computer simulation model. At MRSA colonization rates as low as 1%, a $50 vaccine was cost-effective [≤$50,000 per quality-adjusted life year (QALY) saved] at vaccine efficacy ≥30%, and a $100 vaccine at vaccine efficacy ≥70%. High MRSA prevalence (≥25%) could justify a vaccine price as high as $1000. Our results suggest that a S. aureus vaccine for the pre-operative orthopedic population would be very cost-effective over a wide range of MRSA prevalence and vaccine efficacies and costs.

Original language	English (US)
Pages (from-to)	2465-2471
Number of pages	7
Journal	Vaccine
Volume	28
Issue number	12
DOIs	https://doi.org/10.1016/j.vaccine.2009.12.075
State	Published - Mar 11 2010
Externally published	Yes

Keywords

Computer simulation
Economics
Orthopedic surgery
Staphylococcus aureus
Vaccine

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2009.12.075

Cite this

@article{4b5e089da55d4a63b5c5a3751e35e75b,

title = "Staphylococcus aureus vaccine for orthopedic patients: An economic model and analysis",

abstract = "To evaluate the potential economic value of a Staphylococcus aureus vaccine for pre-operative orthopedic surgery patients, we developed an economic computer simulation model. At MRSA colonization rates as low as 1%, a $50 vaccine was cost-effective [≤$50,000 per quality-adjusted life year (QALY) saved] at vaccine efficacy ≥30%, and a $100 vaccine at vaccine efficacy ≥70%. High MRSA prevalence (≥25%) could justify a vaccine price as high as $1000. Our results suggest that a S. aureus vaccine for the pre-operative orthopedic population would be very cost-effective over a wide range of MRSA prevalence and vaccine efficacies and costs.",

keywords = "Computer simulation, Economics, Orthopedic surgery, Staphylococcus aureus, Vaccine",

author = "Lee, {Bruce Y.} and Wiringa, {Ann E.} and Bailey, {Rachel R.} and Lewis, {G. Jonathan} and Jared Feura and Muder, {Robert R.}",

note = "Funding Information: Supported by the National Institute of General Medical Sciences Models of Infectious Disease Agent Study (MIDAS) through grant 1U54GM088491-0109 . The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. ",

year = "2010",

month = mar,

day = "11",

doi = "10.1016/j.vaccine.2009.12.075",

language = "English (US)",

volume = "28",

pages = "2465--2471",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "12",

}

TY - JOUR

T1 - Staphylococcus aureus vaccine for orthopedic patients

T2 - An economic model and analysis

AU - Lee, Bruce Y.

AU - Wiringa, Ann E.

AU - Bailey, Rachel R.

AU - Lewis, G. Jonathan

AU - Feura, Jared

AU - Muder, Robert R.

N1 - Funding Information: Supported by the National Institute of General Medical Sciences Models of Infectious Disease Agent Study (MIDAS) through grant 1U54GM088491-0109 . The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

PY - 2010/3/11

Y1 - 2010/3/11

N2 - To evaluate the potential economic value of a Staphylococcus aureus vaccine for pre-operative orthopedic surgery patients, we developed an economic computer simulation model. At MRSA colonization rates as low as 1%, a $50 vaccine was cost-effective [≤$50,000 per quality-adjusted life year (QALY) saved] at vaccine efficacy ≥30%, and a $100 vaccine at vaccine efficacy ≥70%. High MRSA prevalence (≥25%) could justify a vaccine price as high as $1000. Our results suggest that a S. aureus vaccine for the pre-operative orthopedic population would be very cost-effective over a wide range of MRSA prevalence and vaccine efficacies and costs.

AB - To evaluate the potential economic value of a Staphylococcus aureus vaccine for pre-operative orthopedic surgery patients, we developed an economic computer simulation model. At MRSA colonization rates as low as 1%, a $50 vaccine was cost-effective [≤$50,000 per quality-adjusted life year (QALY) saved] at vaccine efficacy ≥30%, and a $100 vaccine at vaccine efficacy ≥70%. High MRSA prevalence (≥25%) could justify a vaccine price as high as $1000. Our results suggest that a S. aureus vaccine for the pre-operative orthopedic population would be very cost-effective over a wide range of MRSA prevalence and vaccine efficacies and costs.

KW - Computer simulation

KW - Economics

KW - Orthopedic surgery

KW - Staphylococcus aureus

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=77249155107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77249155107&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.12.075

DO - 10.1016/j.vaccine.2009.12.075

M3 - Article

C2 - 20064479

AN - SCOPUS:77249155107

SN - 0264-410X

VL - 28

SP - 2465

EP - 2471

JO - Vaccine

JF - Vaccine

IS - 12

ER -

Staphylococcus aureus vaccine for orthopedic patients: An economic model and analysis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this